Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luphere Depot in Girls with Central Precocious Puberty
NCT01634321Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2011
- Primary completion
- Aug 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of leuprolide in central precocious puberty (CPP), sponsored by Daewoong Pharmaceutical. Primary endpoint: Percentage of subjects with suppression of peak-stimulated Luteinizing Hormone (LH) concentrations at 24 weeks. Started Jul 2011; status: completed.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT01634321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01634321.